Turing Biosystems


Turing Biosystems is a biotechnology startup that aims to catalyse the convergence of computation and biology in the healthcare industry. We bring the power of networks and advanced algorithms to the analysis of the microbiome and the human organism. Our proprietary AI platform is designed to analyse and understand complex biological systems, using automated reasoning to eliminate training bias. The platform is built on programmable FPGA chips, which makes it ten times faster and more efficient than alternatives, and the AI’s decision trail is fully interrogable. Instead of being handed down answers from some mysterious technological oracle, clinicians and pharma researchers can use the platform as a tool or an assistant, retaining their own agency and expertise. Our two co-founders, Adam and Remy, first met and became best friends through their high school science club. They went on to earn doctorates in, respectively, synthetic biology and software architecture/semiconductor design. The company was established in 2021 and has been supported by the P4 Precision Medicine Accelerator, Capital Enterprise, Stevenage Bioscience Catalyst, and Cancer Research UK, amongst others.